Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) gene therapies are highly promising, such as the onasemnogene abeparvovec (Zolgensma) in spinal muscle atrophy (SMA). We report the first case of fatal systemic thrombotic microangiopathy (TMA) following onasemnogene abeparvovec in a 6-month-old child with SMA type 1, carrying a potential genetic predisposition in the complement factor I gene. Other cases of TMA have recently been reported after onasemnogene abeparvovec and after AAV9 minidystrophin therapy in Duchenne muscular dystrophy. The risk-benefit ratio of this therapy must therefore be assessed. Early recognition of TMA and targeted immunotherapy are fundamental to ensure the safety of patients treated with AAV gene therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Complement activation in response to systemic AAV administration and related acute toxicities has been reported for numerous clinical and preclinical studies (39, 52–56).”
From Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses (2026) · cites this paper as [55]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In clinical trials for DMD and SMA1, patients who received intravenous AAV doses > 1×1014 vector genomes (vg)/kg presented with symptoms of complement activation and a thrombotic microangiopathy (TMA) [54–56].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the complement arm of the immune system has been implemented in recent fatalities in high-dose systemic AAV administration in patients.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Complement activation following AAV administration had not been observed in clinical trials until very high doses were used for systemic delivery, which we now know may trigger life-threatening immunotoxicities.12,13,88,[90][91][92]”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vector-related severe adverse events included severe thrombocytopenia, transaminase elevations, edema, acute endothelial injury, cholestatic, and hepatotoxicity, among others, and showed some similarities to the ones observed in clinical studies of DMD, spinal muscular atrophy, and Xlinked myotubular myopathy.12,13,17,97,98”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [13]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
International, F. H., Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., et al. (2016) · Pediatric Nephrology · doi:10.1007/s00467-015-3076-8 · Cited by 596
Self-citationD'Amico, A., Mercuri, E., Tiziano, F. D., & Bertini, E. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-71 · Cited by 577
Day, J. W., Finkel, R. S., Chiriboga, C. A., Connolly, A. M., Crawford, T. O., Darras, B. T., Iannaccone, S. T., Kuntz, N. L., Peña, L. D. M., Shieh, P. B., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00001-6 · Cited by 494 · cited 2×
“Infantile-onset SMA, or SMA type 1, is typically characterized by decreased motor skills before 6 months of age, progressive respiratory failure, and premature death before the age of 2 years, despite supportive care.1 Onasemnogene abeparvovec (Zolgensma, Novartis, Basel, Switzerland), the adeno-associated virus (AAV)…”
BackgroundComplement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome
Fremeaux-Bacchi, V, Dragon-Durey, M.-A., Blouin, J., Vigneau, C., Kuypers, D., Boudailliez, B., Loirat, C., Rondeau, E., & Fridman, W. H. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.019083 · Cited by 339
Self-citationChand, D. H., Zaidman, C., Arya, K., Millner, R., Farrar, M. A., Mackie, F. E., Goedeker, N. L., Dharnidharka, V. R., Dandamudi, R., & Reyna, S. P. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.11.054 · Cited by 210 · cited 3×
“Three TMA cases induced by this therapy were reported after our current report of this patient.(5) Our case shows similarities to the other reported cases: TMA occurred rapidly after treatment (D7-D10) and was predominated by acute renal failure, and further investigations showed an increase in sC5b9.”
BackgroundResultInfluentialThe genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy
Jodele, S., Zhang, K., Zou, F., Laskin, B., Dandoy, C. E., Myers, K. C., Lane, A., Meller, J., Medvedovic, M., Chen, J., et al. (2016) · Blood · doi:10.1182/blood-2015-08-663435 · Cited by 190 · cited 1×
“However, our observation suggests that onasemnogene abeparvovec may be the “second hit” in a genetic background that predisposes to the occurrence and the severity of TMA clinical symptoms, as described after hematopoietic stem cell transplant.(13)”
BackgroundKavanagh, D., Yu, Y., Schramm, E. C., Triebwasser, M., Wagner, E. K., Raychaudhuri, S., Daly, M. J., Atkinson, J. P., & Seddon, J. M. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv091 · Cited by 124
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
Day, J. W., Mendell, J. R., Mercuri, E., Finkel, R. S., Strauss, K. A., Kleyn, A., Tauscher-Wisniewski, S., Tukov, F. F., Reyna, S. P., & Chand, D. H. (2021) · Drug Safety · doi:10.1007/s40264-021-01107-6 · Cited by 119
Soluble C5b-9 as a Biomarker for Complement Activation in Atypical Hemolytic Uremic Syndrome
Bu, F., Meyer, N. C., Zhang, Y., Borsa, N. G., Thomas, C. P., Nester, C., & Smith, R. J. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.02.326 · Cited by 60 · cited 1×
“It is also proposed as a biomarker of disease progression in typical HUS or TMA after hematopoietic stem cell transplantation.(16,17) Eculizumab, the recommended treatment for complement-associated TMA, had mixed effects on the laboratory results in our patient: a slight increase in platelet count and a decrease in LD…”
Background
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“413 It should be noted that as of Jan 13, 2022, nine cases of TMA were recorded out of over 1400 patients (~0.6”
BackgroundInfluentialLethal immunotoxicity in high-dose systemic AAV therapy
Duan, D. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.015 · Cited by 240
AAV-based in vivo gene therapy for neurological disorders
Ling, Q., Herstine, J. A., Bradbury, A., & Gray, S. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00766-7 · Cited by 197
Successes and challenges in clinical gene therapy
Kohn, D. B., Chen, Y. Y., & Spencer, M. J. (2023) · Gene Therapy · doi:10.1038/s41434-023-00390-5 · Cited by 184
“Based on reports from P fi zer, Solid Biosciences, and Novartis [111, 112], there is ample evidence that this adverse event likely relies on the presence of anti-AAV antibodies [113].”
ResultDrug delivery systems for CRISPR-based genome editors
Madigan, V., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 172
“Furthermore, complement-driven systemic thrombotic microangiopathy has been observed in patients following administration of Zolgensma and other AAV-based therapeutics, including one recent fatal case 124 .”
Background
Metadata
- Authors
- Guillou, J., de Pellegars, A., Porcheret, F., Frémeaux-Bacchi, V., Allain-Launay, E., Debord, C., Denis, M., Péréon, Y., Barnérias, C., Desguerre, I., Roussey, G., & Mercier, S.
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- 2CHU Angers, Fédération de Pédiatrie, Angers, France;
- 3Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service d'Immunologie, Paris, France;
- 1Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France;
- Centre National de la Recherche Scientifique (FR)
- Hôpital Necker-Enfants Malades (FR)
- Corresponding author
- Mercier, Sandra
- ORCID
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2022-07-22
- Volume
- 6
- Issue
- 14
- Pages
- 4266-4270
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC9327533
- OpenAlex
- W4280574529
- Cited by
- 166
- References
- 13
- Citations by year
- 2026: 37 · 2025: 41 · 2024: 38 · 2023: 42 · 2022: 8
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- thrombotic microangiopathy, onasemnogene abeparvovec, adeno-associated virus gene therapy, spinal muscular atrophy type 1, complement factor I, Duchenne muscular dystrophy, pediatric patient safety, targeted immunotherapy
- MeSH terms
- Dependovirus, Humans, Immunotherapy, Infant, Muscular Atrophy, Spinal, Genetic Therapy, Fatal Outcome, Thrombotic Microangiopathies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. https://app.cochat.ai/papers/10.1182/bloodadvances.2021006419
- The paper
- Guillou, J., de Pellegars, A., Porcheret, F., Frémeaux-Bacchi, V., Allain-Launay, E., Debord, C., Denis, M., Péréon, Y., Barnérias, C., Desguerre, I., Roussey, G., & Mercier, S. (2022). Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Advances. https://doi.org/10.1182/bloodadvances.2021006419
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.